These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 35129005)
1. Electrophilic warheads in covalent drug discovery: an overview. Péczka N; Orgován Z; Ábrányi-Balogh P; Keserű GM Expert Opin Drug Discov; 2022 Apr; 17(4):413-422. PubMed ID: 35129005 [TBL] [Abstract][Full Text] [Related]
2. Arylfluorosulfate-Based Electrophiles for Covalent Protein Labeling: A New Addition to the Arsenal. Martín-Gago P; Olsen CA Angew Chem Int Ed Engl; 2019 Jan; 58(4):957-966. PubMed ID: 30024079 [TBL] [Abstract][Full Text] [Related]
3. Covalent drug discovery using sulfur(VI) fluoride exchange warheads. Huang H; Jones LH Expert Opin Drug Discov; 2023 Jul; 18(7):725-735. PubMed ID: 37243622 [TBL] [Abstract][Full Text] [Related]
4. Development and application of novel electrophilic warheads in target identification and drug discovery. Liu Y; Lv S; Peng L; Xie C; Gao L; Sun H; Lin L; Ding K; Li Z Biochem Pharmacol; 2021 Aug; 190():114636. PubMed ID: 34062128 [TBL] [Abstract][Full Text] [Related]
5. The expanding repertoire of covalent warheads for drug discovery. Mehta NV; Degani MS Drug Discov Today; 2023 Dec; 28(12):103799. PubMed ID: 37839776 [TBL] [Abstract][Full Text] [Related]
6. Covalent Docking in Drug Discovery: Scope and Limitations. Scarpino A; Ferenczy GG; Keserű GM Curr Pharm Des; 2020; 26(44):5684-5699. PubMed ID: 33155894 [TBL] [Abstract][Full Text] [Related]
7. Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery. Zhao Z; Bourne PE Pharmaceuticals (Basel); 2022 Oct; 15(11):. PubMed ID: 36355497 [TBL] [Abstract][Full Text] [Related]
8. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. Gehringer M; Laufer SA J Med Chem; 2019 Jun; 62(12):5673-5724. PubMed ID: 30565923 [TBL] [Abstract][Full Text] [Related]
9. Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update. Hillebrand L; Liang XJ; Serafim RAM; Gehringer M J Med Chem; 2024 May; 67(10):7668-7758. PubMed ID: 38711345 [TBL] [Abstract][Full Text] [Related]
10. A road map for prioritizing warheads for cysteine targeting covalent inhibitors. Ábrányi-Balogh P; Petri L; Imre T; Szijj P; Scarpino A; Hrast M; Mitrović A; Fonovič UP; Németh K; Barreteau H; Roper DI; Horváti K; Ferenczy GG; Kos J; Ilaš J; Gobec S; Keserű GM Eur J Med Chem; 2018 Dec; 160():94-107. PubMed ID: 30321804 [TBL] [Abstract][Full Text] [Related]
11. Selective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads. Wang J; Zhou S; Cheng Y; Cheng L; Qin Y; Zhang Z; Bi A; Xiang H; He X; Tian X; Liu W; Zhang J; Peng C; Zhu Z; Huang M; Li Y; Zhuang G; Tan L J Med Chem; 2023 Feb; 66(4):2608-2621. PubMed ID: 36723914 [TBL] [Abstract][Full Text] [Related]
12. CovPDB: a high-resolution coverage of the covalent protein-ligand interactome. Gao M; Moumbock AFA; Qaseem A; Xu Q; Günther S Nucleic Acids Res; 2022 Jan; 50(D1):D445-D450. PubMed ID: 34581813 [TBL] [Abstract][Full Text] [Related]
14. Characterising covalent warhead reactivity. Martin JS; MacKenzie CJ; Fletcher D; Gilbert IH Bioorg Med Chem; 2019 May; 27(10):2066-2074. PubMed ID: 30975501 [TBL] [Abstract][Full Text] [Related]
15. Investigation of the Compatibility between Warheads and Peptidomimetic Sequences of Protease Inhibitors-A Comprehensive Reactivity and Selectivity Study. Müller P; Meta M; Meidner JL; Schwickert M; Meyr J; Schwickert K; Kersten C; Zimmer C; Hammerschmidt SJ; Frey A; Lahu A; de la Hoz-Rodríguez S; Agost-Beltrán L; Rodríguez S; Diemer K; Neumann W; Gonzàlez FV; Engels B; Schirmeister T Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108388 [TBL] [Abstract][Full Text] [Related]
16. Recent progress in covalent warheads for in vivo targeting of endogenous proteins. Shindo N; Ojida A Bioorg Med Chem; 2021 Oct; 47():116386. PubMed ID: 34509863 [TBL] [Abstract][Full Text] [Related]
17. An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases. Petri L; Egyed A; Bajusz D; Imre T; Hetényi A; Martinek T; Ábrányi-Balogh P; Keserű GM Eur J Med Chem; 2020 Dec; 207():112836. PubMed ID: 32971426 [TBL] [Abstract][Full Text] [Related]